Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial

IMPORTANCE: There are no medical interventions for the orphan disease CYLD cutaneous syndrome (CCS). Transcriptomic profiling of CCS skin tumors previously highlighted tropomyosin receptor kinases (TRKs) as candidate therapeutic targets. OBJECTIVE: To investigate if topical targeting of TRK with an...

Descripción completa

Detalles Bibliográficos
Autores principales: Danilenko, Marina, Stamp, Elaine, Stocken, Deborah D., Husain, Akhtar, Zangarini, Monique, Cranston, Amy, Stones, Robert, Sinclair, Naomi, Hodgson, Kirsty, Bowett, Susan A., Roblin, David, Traversa, Silvio, Plummer, Ruth, Veal, Gareth, Langtry, James A. A., Ashworth, Alan, Burn, John, Rajan, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2018
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128505/
https://www.ncbi.nlm.nih.gov/pubmed/29955768
http://dx.doi.org/10.1001/jamadermatol.2018.1610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128505/
https://www.ncbi.nlm.nih.gov/pubmed/29955768
http://dx.doi.org/10.1001/jamadermatol.2018.1610

Ejemplares similares